The WHO clearly identifies
tumors as a curable or a
chronic disease. The use of natural agents in
cancer prevention and
therapy is currently playing an important role. Our laboratory has been investigating various natural phenolic compounds, including
grifolin,
neoalbaconol and
epigallocatechin-3-gallate (EGCG). In the present review, we focus on the anticancer activities and the molecular mechanisms of these compounds.
Grifolin, a secondary metabolite isolated from the mushroom Albatrellus confluens, has been shown to inhibit cell growth and induce cell cycle arrest in multiple
cancer cell lines by targeting
extracellular signal-regulated kinase 1 or by upregulating
death-associated protein kinase 1 (DAPK1) via p53. We also demonstrated that
neoalbaconol, a novel small-molecular compound with a
drimane-type
sesquiterpenoid structure obtained from Albatrellus confluens, regulates cell metabolism by targeting
3-phosphoinositide-dependent protein kinase 1 (PDK1) and inhibits
cancer cell growth. EGCG, a well known
catechin found in
tea, has gained much attention for its anticancer effects. Previously, we found that it regulates EBV lytic
infection through the phosphoinositide-3
kinase/Akt (PI3K/Akt) and
mitogen-activated protein kinase (MAPK) pathways in EBV-positive
cancer cells. Therefore, these natural agents could be used as potential leading compounds in the prevention of
tumor progression and/or EBV-related
cancer.